Cargando…

Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer

SIMPLE SUMMARY: Initial clinical observations revealed strikingly longer follow-up for metastatic non-small-cell lung cancer (NSCLC) patients receiving nivolumab infusions predominantly in the morning as compared to those treated in the afternoon. Prior experimental and human studies have demonstrat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karaboué, Abdoulaye, Collon, Thierry, Pavese, Ida, Bodiguel, Viviane, Cucherousset, Joel, Zakine, Elda, Innominato, Pasquale F., Bouchahda, Mohamed, Adam, René, Lévi, Francis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870559/ https://www.ncbi.nlm.nih.gov/pubmed/35205644 http://dx.doi.org/10.3390/cancers14040896

Ejemplares similares

Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer
por: Bouchahda, Mohamed, et al.
Publicado: (2020)

Sex‐dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial
por: Innominato, Pasquale F., et al.
Publicado: (2020)

Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5‐fluorouracil and leucovorin combination as first‐ or second‐line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial
por: Innominato, Pasquale F., et al.
Publicado: (2020)

Circadian and chemotherapy-related changes in urinary modified nucleosides excretion in patients with metastatic colorectal cancer
por: Dulong, S., et al.
Publicado: (2021)

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)
por: Lévi, Francis, et al.
Publicado: (2017)

Clinical Relevance of the First Domomedicine Platform Securing Multidrug Chronotherapy Delivery in Metastatic Cancer Patients at Home: The inCASA European Project
por: Innominato, Pasquale F, et al.
Publicado: (2016)

Circadian rest‐activity rhythm as an objective biomarker of patient‐reported outcomes in patients with advanced cancer
por: Innominato, Pasquale F., et al.
Publicado: (2018)

Relevance of a Mobile Internet Platform for Capturing Inter- and Intrasubject Variabilities in Circadian Coordination During Daily Routine: Pilot Study
por: Komarzynski, Sandra, et al.
Publicado: (2018)

A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer
por: Ulusakarya, Ayhan, et al.
Publicado: (2020)

Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
por: Kraehenbuehl, Lukas, et al.
Publicado: (2022)

Optimizing circadian drug infusion schedules towards personalized cancer chronotherapy
por: Hill, Roger J. W., et al.
Publicado: (2020)

Impact of country of birth on genetic testing of metastatic lung adenocarcinomas in France: African women exhibit a mutational spectrum more similar to Asians than to Caucasians
por: Saffroy, Raphael, et al.
Publicado: (2017)

Treatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical Outcomes
por: Wells, Leah, et al.
Publicado: (2022)

Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
por: D’Angelo, Sandra P., et al.
Publicado: (2022)

Systems Chronotherapeutics
por: Ballesta, Annabelle, et al.
Publicado: (2017)

Immune checkpoint inhibitor-induced diabetes mellitus with nivolumab
por: Zand Irani, Anis, et al.
Publicado: (2023)

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
por: Girardi, Daniel M., et al.
Publicado: (2022)

Relevance of internal time and circadian robustness for cancer patients
por: Ortiz-Tudela, Elisabet, et al.
Publicado: (2016)

Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab
por: Bukamur, Hazim, et al.
Publicado: (2020)

Hidden Markov models for monitoring circadian rhythmicity in telemetric activity data
por: Huang, Qi, et al.
Publicado: (2018)

Metastatic Merkel cell carcinoma response to nivolumab
por: Walocko, Frances M., et al.
Publicado: (2016)

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
por: Oro-Ayude, Marcos, et al.
Publicado: (2020)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Nivolumab in Metastatic Non–Small Cell Lung Cancer
por: Deel, Andrea
Publicado: (2016)

Efficacy and safety of nivolumab for metastatic biliary tract cancer
por: Gou, Miaomiao, et al.
Publicado: (2019)

First-line treatment of metastatic melanoma: role of nivolumab
por: Force, Jeremy, et al.
Publicado: (2017)

Erratum to: Metastatic Merkel cell carcinoma response to nivolumab
por: Walocko, Frances M., et al.
Publicado: (2017)

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
por: Diab, Adi, et al.
Publicado: (2021)

Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies
por: Gunawan, Florence, et al.
Publicado: (2018)

A Case of Acute Heart Failure due to Immune Checkpoint Blocker Nivolumab
por: Sharma, Munish, et al.
Publicado: (2019)

SUN-388 Immune Checkpoint Inhibitor Nivolumab in Advanced or Recurrent Adrenocortical Carcinoma
por: Akunjee, Munaza, et al.
Publicado: (2019)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

Immune Checkpoint Inhibitor Induced Pericarditis and Encephalitis in a Patient Treated With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report and Review of the Literature
por: Braden, Jorja, et al.
Publicado: (2021)

Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)
por: Reid, Tony, et al.
Publicado: (2023)

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
por: Paoluzzi, L., et al.
Publicado: (2016)

Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
por: Han, Nanumi, et al.
Publicado: (2018)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab
por: Catalano, Martina, et al.
Publicado: (2023)

Multicentre, interventional, single-arm study protocol of telemonitored circadian rhythms and patient-reported outcomes for improving mFOLFIRINOX safety in patients with pancreatic cancer (MultiDom, NCT04263948)
por: Bouchahda, Mohamed, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rqkah9huamv2mg4slegp20etvl